Compare Deutsche Bank AG (DB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Novavax Inc — how do they compare? Deutsche Bank AG trades at $33.66 (market cap $62.42B), while Novavax Inc trades at $12.74 (market cap $1.82B). The key difference: Deutsche Bank AG is far larger — about 34.3× Novavax Inc's market cap, and Deutsche Bank AG pays a 3.46% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Novavax Inc for 59 Days on average.
| DB | NVAX | |
|---|---|---|
Market Cap | $62.42B | $1.82B |
Volume | 2,918,760 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $41.56 | $12.56 |
52-Week Low | $28.37 | $6.22 |
Typical Hold Time | 80 Days | 59 Days |
Enterprise Value | $77.06B | $1.39B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.58, showing minimal daily movement (+0.09%). The stock presents mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.09 and P/B of 0.71. Recent earnings show volatility with a Q2 2026 miss but strong Q1 2026 beat. The company demonstrates improved financial health with 2025 net cash flow of $7.61B and rising revenue trends from $30.0B in 2024 to $32.1B in 2025.
DB offers value investment potential with below-market valuations and positive cash flow generation, though technical weakness and mixed analyst sentiment (21% buy, 58% hold) suggest cautious optimism. Key risks include investment banking revenue volatility and significant workforce retirement challenges. The path to 2028 targets depends on wealth management growth and cost control execution.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
